Table 1.
Patient and tumour characteristics
| Characteristic | Patients (n = 453) | |
|---|---|---|
| Median | Min–Max | |
| Age at diagnosis (years) | 57 | 30–79 |
| Mean | Std | |
| BMI at enrolment | 26.5 | 5.1 |
| Patients with comorbiditya | n | % |
| Any comorbidityb | 254 | 56.1% |
| CCI =0c | 354 | 78.1% |
| CCI ≥1c | 99 | 21.9% |
| Hypertension | 130 | 28.7% |
| Diabetes | 36 | 7.9% |
| Menopausal statusd | ||
| Premenopausal | 127 | 28.0% |
| Perimenopausal | 18 | 4.0% |
| Postmenopausal | 260 | 57.4% |
| Unknown | 48 | 10.6% |
| Receptor statusa | ||
| HR-positive, HER2-negative | 237 | 52.3% |
| HR-positive, HER2-positive | 76 | 16.8% |
| HR-negative, HER2-positive | 38 | 8.4% |
| Triple negative | 86 | 19.0% |
| Unknown | 16 | 3.5% |
| Tumour stagea,e | ||
| I | 118 | 26.0% |
| II | 201 | 44.4% |
| III | 71 | 15.7% |
| Not determined/unknownf | 63 | 13.9% |
| Nodal stagea | ||
| Positive | 222 | 49.0% |
| Negative (N0) | 217 | 47.9% |
| Unknown (NX + missing) | 14 | 3.1% |
| Location of primary tumoura | ||
| Right | 232 | 51.2% |
| Left | 211 | 46.6% |
| Both | 10 | 2.2% |
BMI body mass index in kg/m2, HR hormone receptor, HER2 human epidermal growth factor receptor 2, Max maximum, Min minimum, N regional lymph node, Std standard deviation
aAt diagnosis
bComorbidity according to Charlson [17] or additional concomitant diseases
cCharlson Comorbidity Index (CCI) according to Quan [18]
dAt enrolment
eTumour stage according to AJCC/UICC 7th edition
fFor some patients, the exact stage could not be determined because of unknown parameters (TX, NX, MX)